Sarah Gheuens insider trades: Agios Pharmaceuticals (AGIO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sarah reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 26, 2026 | AGIO | ↓ Sell | 7,866 | $37.69 | $296K | Direct | Oct 28, 2026 (2d) |
| Oct 22, 2026 | AGIO | ↓ Sell | 1,989 | $37.53 | $75K | Direct | Oct 23, 2026 (1d) |
| Apr 2, 2026 | AGIO | ↓ Sell | 2,940 | $34.71 | $102K | Direct | Apr 6, 2026 (4d) |
| Dec 30, 2025 | AGIO | ↓ Sell | 2,932 | $27.09 | $79K | Direct | Jan 2, 2026 (3d) |
| Nov 11, 2025 | AGIO | ↓ Sell | 2,454 | $43.78 | $107K | Direct | Nov 13, 2025 (2d) |
| Oct 30, 2025 | AGIO | ↓ Sell | 200 | $43.81 | $9K | Direct | Nov 3, 2025 (4d) |
| Oct 27, 2025 | AGIO | ↓ Sell | 3,302 | $43.92 | $145K | Direct | Oct 29, 2025 (2d) |
| Jul 9, 2025 | AGIO | ↓ Sell | 11,914 | $37.99 | $453K | Direct | Jul 11, 2025 (2d) |
| Jul 1, 2025 | AGIO | ↓ Sell | 4,091 | $34.17 | $140K | Direct | Jul 3, 2025 (2d) |
| Jun 24, 2025 | AGIO | ↓ Sell | 2,909 | $33.54 | $98K | Direct | Jun 26, 2025 (2d) |
| Mar 3, 2025 | AGIO | ↓ Sell | 4,005 | $35.54 | $142K | Direct | Mar 4, 2025 (1d) |
| Jul 1, 2024 | AGIO | ↓ Sell | 3,705 | $43.85 | $162K | Direct | Jul 3, 2024 (2d) |
| Mar 5, 2024 | AGIO | ↓ Sell | 2,642 | $32.57 | $86K | Direct | Mar 5, 2024 (0d) |
| Feb 14, 2024 | AGIO | ↓ Sell | 642 | $25.14 | $16K | Direct | Feb 14, 2024 (0d) |
| Jan 24, 2024 | AGIO | ↓ Sell | 1,708 | $21.64 | $37K | Direct | Jan 24, 2024 (0d) |
| Jan 9, 2024 | AGIO | ↓ Sell | 1,789 | $22.99 | $41K | Direct | Jan 9, 2024 (0d) |
| Jun 30, 2023 | AGIO | ↓ Sell | 1,707 | $28.36 | $48K | Direct | Jun 30, 2023 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AGIO insiders
Open-market trades in the last 12 months
About Sarah Gheuens's insider trades
Sarah Gheuens is Chief Medical Officer at Agios Pharmaceuticals (AGIO). Since Jun 30, 2023, Sarah has reported no open-market purchases and 17 sales worth $2.0M on SEC Form 4. In the last 12 months: 5 sales ($660K).
Their filings also include option exercises (25 filings), grants and awards (9 filings), shares withheld for taxes (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AGIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.